ISSN: E-2314-7326
P-2314-7334

神経感染症

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • Jゲートを開く
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • キャブダイレクト
  • パブロン
  • ジュネーブ医学教育研究財団
  • ICMJE
このページをシェアする

抽象的な

Parkinson's Disease Associated with Cognitive Decline

Vincenza Aurelian

Increasing events or objects that prove something hints that gangliosides act as important people who try to settle an argument in both demyelination and remyelination. Goal: The purpose of the present study was to ask lots of questions about/try to find the truth about the presence of IgM disease-fighters against GM1, GD1b and GQ1b gangliosides in the sera of in patients who suffered from Parkinson's disease in relationship with the medicine-based limits/guidelines. The present research is based on the act of asking questions and trying to find the truth about something for anti-ganglioside disease-fighters and healthy age-matched people, as usual/ commonly and regular/ healthy controls, using Enzyme-Linked Immuno-Sorbent tests/things to be tested. The patients showed/told about increased levels of the tested disease-fighters, compared to usual/ commonly and regular/ healthy controls. A relationship between IgM anti-GM1 and the level of thinking-related damage/weakness Minimental State Examination; Brought together as one Parkinson's Disease Rating Scale I was also saw/heard/became aware of. An off to the side neuroimmune response may happen in patients who suffer from Parkinson's disease especially those with thinking-related damage/weakness. Further (act of asking questions and trying to find the truth about something) is needed to establish a direct connection between that unable to be harmed response and disease how a disease works. One of the most impactful non-motor visible signs of Parkinson's disease (PD) is thinking-related damage/weakness. Thinking-related decline in PD exists as a (something that continues from one extreme to the other), with signs of sickness ranging from (usual/ commonly and regular/ healthy) thinking to mild thinking-related damage/weakness (MCI) and finally severe problems with thinking and living (PDD). MCI is related to medicine and science group of different things mixed together and its development or increase over time/series of events or things differs/changes with cases returning to usual/ commonly and regular/ healthy thinking. Opposite from what's expected, when severe problems with thinking and living happens, the decline is usually fast and made a prejudiced mental picture. The combination of Lewy and Brain disease disease/the study of disease is the most strong and healthy disease-related relate of PDD. There are no approved drugs for PD-MCI and the benefit from the only approved showing signs of sickness treatment for PDD is modest.